Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Autoimmune disease flares associated with better cancer outcomes in patients on checkpoint inhibitors
EULAR Congress 2018, Abstract OP0196.
Key clinical point: Cancer patients who take a checkpoint inhibitor and have a preexisting autoimmune disease were significantly more likely to have a disease flare but also a better cancer outcome than were those without preexisting disease.
Major finding: In those with a disease flare, progression-free and overall survival were significantly improved (P = .016 and P = .004, respectively).
Study details: Retrospective multicenter study.
Disclosures: The study was not industry funded. Ms. Tison reported no potential conflicts of interest.
Citation:
EULAR Congress 2018, Abstract OP0196.